C2 PHARMA, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), announces the approval of a Certificate of Suitability (CEP) for ...

COS (CEP) awarded by EDQM. Patent application filed for innovative process. Optimum particle size distribution (PSD) achieved for digoxin formulation homogeneity, dissolution and bioavailability.

Shilpa Medicare share price rose in the early trade on October 4 after the company's arm received certification from a European medical agency. At 09:24am, Shilpa Medicare was quoting at Rs 812.75 ...

In addition, regulatory authorities - such as EDQM - do not accept post production micronization on APIs if not fully described in the API dossier (DMF) or COS (CEP) as it potentially changes the ...